Nature Communications (Aug 2016)
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
- Xia Ding,
- Arnab Ray Chaudhuri,
- Elsa Callen,
- Yan Pang,
- Kajal Biswas,
- Kimberly D. Klarmann,
- Betty K. Martin,
- Sandra Burkett,
- Linda Cleveland,
- Stacey Stauffer,
- Teresa Sullivan,
- Aashish Dewan,
- Hanna Marks,
- Anthony T. Tubbs,
- Nancy Wong,
- Eugen Buehler,
- Keiko Akagi,
- Scott E. Martin,
- Jonathan R. Keller,
- André Nussenzweig,
- Shyam K. Sharan
Affiliations
- Xia Ding
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Arnab Ray Chaudhuri
- Laboratory of Genome Integrity, National Cancer Institute, NIH
- Elsa Callen
- Laboratory of Genome Integrity, National Cancer Institute, NIH
- Yan Pang
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Kajal Biswas
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Kimberly D. Klarmann
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Betty K. Martin
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Sandra Burkett
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Linda Cleveland
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Stacey Stauffer
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Teresa Sullivan
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Aashish Dewan
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Hanna Marks
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- Anthony T. Tubbs
- Laboratory of Genome Integrity, National Cancer Institute, NIH
- Nancy Wong
- Laboratory of Genome Integrity, National Cancer Institute, NIH
- Eugen Buehler
- Chemical Genomics Center, National Center for Advancing Translational Sciences, NIH
- Keiko Akagi
- Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center
- Scott E. Martin
- Chemical Genomics Center, National Center for Advancing Translational Sciences, NIH
- Jonathan R. Keller
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- André Nussenzweig
- Laboratory of Genome Integrity, National Cancer Institute, NIH
- Shyam K. Sharan
- Mouse Cancer Genetics Program, National Cancer Institute, NIH
- DOI
- https://doi.org/10.1038/ncomms12425
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 12
Abstract
The PARP inhibitor olaparib is an approved treatment method for women with BRCA1 and BRCA2 mutation associated cancers. Here the authors show that olaparib can contribute to synthetic viability of cells if PARP1 is inhibited before BRCA2 loss.
